Panobinostat (LBH589)

For research use only. Not for use in humans.

目录号：S1030 别名： NVP-LBH589 中文名称：帕比司他

Panobinostat (LBH589) Chemical Structure

CAS No. 404950-80-7

Panobinostat (LBH589, NVP-LBH589)是一种新型的，广谱HDAC抑制剂，无细胞试验中IC50为5 nM。Panobinostat (LBH589) 可诱导自噬和凋亡。Panobinostat 可以有效地破坏体内 HIV 的潜伏期。Phase 3。

规格

价格

库存

购买数量

10mg	RMB 731.86	现货
50mg	RMB 2189.52	现货
200mg	RMB 5485.18	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Panobinostat (LBH589)发表文献269篇：

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 36(5):528-544

PubMed: 31631026 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):782-797

PubMed: 31085178 ( click the link to review the publication )

Nat Immunol, 2019, 20(7):835-851

PubMed: 31160797 ( click the link to review the publication )

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Nat Genet, 2018, 50(10):1442-1451

PubMed: 30224647 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cell, 2014, 20;159(5):1110-1125.

PubMed: 25416949 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Blood, 2020, 10.1182/blood.2019004332

PubMed: 32844992 ( click the link to review the publication )

Nat Commun, 2020, 11(1):583

PubMed: 31996670 ( click the link to review the publication )

Sci Immunol, 2020, 5(50):eabb5168

PubMed: 32826342 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33046

PubMed: 32599665 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 9;39(1):105

PubMed: 32517809 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 5;12(6):E1478

PubMed: 32517016 ( click the link to review the publication )
Cancers (Basel), 2020, 12(10)E2857

PubMed: 33023028 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2903

PubMed: 33050470 ( click the link to review the publication )

PLoS Pathog, 2020, 16(3):e1008442

PubMed: 32196533 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32059481 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(6):1827-1843

PubMed: 32642294 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:296

PubMed: 32195191 ( click the link to review the publication )

Sci Rep, 2020, 10(1):3470

PubMed: 32103105 ( click the link to review the publication )

Fluids Barriers CNS, 2020, 2;17(1):37

PubMed: 32487241 ( click the link to review the publication )

Exp Hematol, 2020, 81:32-41

PubMed: 31954171 ( click the link to review the publication )

J Thromb Haemost, 2020, 10.1111/jth.15012

PubMed: 32662223 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04021-y

PubMed: 31894347 ( click the link to review the publication )

Blood Adv, 2020, 4(18):4393-4405

PubMed: 32926125 ( click the link to review the publication )

EBioMedicine, 2020, 102853

PubMed: 32654992 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01408-7

PubMed: 32733069 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:4429-4439

PubMed: 32606937 ( click the link to review the publication )

Cancer Cell, 2020, 38(1):44-59.e9

PubMed: 32663469 ( click the link to review the publication )

Commun Biol, 2020, 3(1):363

PubMed: 32647372 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

J Med Chem, 2020, 10.1021/acs.jmedchem.9b01888

PubMed: 32803970 ( click the link to review the publication )

Cell Res, 2019, 29(4):286-304

PubMed: 30631154 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3319

PubMed: 31346162 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )
Leukemia, 2019, 10.1038/s41375-019-0525-6

PubMed: 31358854 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(26):12986-12995

PubMed: 31182587 ( click the link to review the publication )

Neuro Oncol, 2019, 10.1093/neuonc/noz215

PubMed: 31711240 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Clin Infect Dis, 2019, 10.1093/cid/ciz108

PubMed: 30753360 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cell Rep, 2019, 29(9):2783-2795

PubMed: 31775045 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):185

PubMed: 31053152 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

PLoS Pathog, 2019, 15(8):e1007991

PubMed: 31425551 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):134

PubMed: 31801577 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):185-195

PubMed: 30301863 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Oncologist, 2019, 24(8):e740-e748

PubMed: 30696721 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2019, 1865(6):1666-1676

PubMed: 30954557 ( click the link to review the publication )

J Biomed Nanotechnol, 2019, 15(5):979-992

PubMed: 30890229 ( click the link to review the publication )
Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Biomolecules, 2019, 9(5)

PubMed: 31083537 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18970-18984

PubMed: 30916359 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

J Virol, 2019, 93(24)

PubMed: 31578289 ( click the link to review the publication )

Antimicrob Agents Chemother, 2019, 63(2)

PubMed: 30455231 ( click the link to review the publication )

Epigenetics Chromatin, 2019, 12(1):18

PubMed: 30871586 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Mol Carcinog, 2019, 58(12):2230-2240

PubMed: 31478563 ( click the link to review the publication )

Mol Carcinog, 2019, 58(2):234-246

PubMed: 30303565 ( click the link to review the publication )

Virus Res, 2019, 269:197631

PubMed: 31136823 ( click the link to review the publication )

Mol Genet Genomic Med, 2019, 7(5):e613

PubMed: 30891950 ( click the link to review the publication )

Childs Nerv Syst, 2019, 35(5):823-831

PubMed: 30815722 ( click the link to review the publication )

J Nanobiotechnology, 2019, 17(1):69

PubMed: 31113488 ( click the link to review the publication )

J Virus Erad, 2019, 5(3):133-137

PubMed: 31700655 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4866

PubMed: 30451831 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(1):120-129.

PubMed: 29066507 ( click the link to review the publication )
Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Oncogene, 2018, 37(50):6414-6424

PubMed: 30068939 ( click the link to review the publication )

Oncogene, 2018, 37(6):722-731

PubMed: 29059175 ( click the link to review the publication )

Cancer Lett, 2018, 417:152-160

PubMed: 29306016 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):381-392

PubMed: 28839000 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1705-1716

PubMed: 29748211 ( click the link to review the publication )

Cell Oncol (Dordr), 2018, 41(2):201-212

PubMed: 29260509 ( click the link to review the publication )

J Immunol, 2018, 201(3):1086-1096

PubMed: 29914885 ( click the link to review the publication )

J Virol, 2018, 92(13)

PubMed: 29643247 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9472

PubMed: 29930256 ( click the link to review the publication )

J Proteome Res, 2018, 17(4):1436-1451

PubMed: 29564889 ( click the link to review the publication )

Biomed Pharmacother, 2018, 100:509-520

PubMed: 29494986 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

J Ethnopharmacol, 2018, 211:267-277

PubMed: 28970153 ( click the link to review the publication )

Exp Cell Res, 2018, 363(2):196-207

PubMed: 29317217 ( click the link to review the publication )
PLoS One, 2018, 13(12):e0208147

PubMed: 30592723 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Dis Markers, 2018, 2018:3810108

PubMed: 30647797 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(1):61-74

PubMed: 29049036 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36530-36541

PubMed: 30559935 ( click the link to review the publication )

Oncotarget, 2018, 9(5):6450-6462

PubMed: 29464084 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28586-28598

PubMed: 29983882 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 100(1):174-187

PubMed: 29107335 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )

Nat Commun, 2017, 8(1):728

PubMed: 28959017 ( click the link to review the publication )

Cancer Res, 2017, 77(11):3027-3039

PubMed: 28363998 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

Stem Cell Reports, 2017,

PubMed: 29033304 ( click the link to review the publication )

Cell Death Dis, 2017,

PubMed: 29022919 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Arch Toxicol, 2017, 91(1):365-391

PubMed: 27015953 ( click the link to review the publication )

Arch Toxicol, 2017, 91(2):839-864

PubMed: 27188386 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Br J Haematol, 2017, 178(5):728-738

PubMed: 28480959 ( click the link to review the publication )
Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

Int J Nanomedicine, 2017, 12:1385-1399

PubMed: 28260886 ( click the link to review the publication )

J Biol Chem, 2017, 292(9):3683-3691

PubMed: 28087699 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

J Neuropathol Exp Neurol, 2017,

PubMed: 29136455 ( click the link to review the publication )

Exp Cell Res, 2017, 350(1):218-225

PubMed: 27914787 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):42-50

PubMed: 28107750 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169485

PubMed: 28052119 ( click the link to review the publication )

Horm Cancer, 2017, 8(4):257-267

PubMed: 28516379 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1575-1583

PubMed: 29296798 ( click the link to review the publication )

Oncotarget, 2017, 8(50):87307-87316

PubMed: 29152082 ( click the link to review the publication )

Genom Data, 2017, 12:14-16

PubMed: 28239551 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17833-17848

PubMed: 28147319 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3908-3921

PubMed: 29423093 ( click the link to review the publication )

Oncotarget, 2017, 8(18):30019-30029

PubMed: 28415789 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56747-56757

PubMed: 28915627 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94569-94579

PubMed: 29212250 ( click the link to review the publication )
Methods Mol Biol, 2017, 1510:127-148

PubMed: 27761818 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(3):1159-1176

PubMed: 28180300 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(10):2534-44

PubMed: 26733615 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(46):13162-13167

PubMed: 27799547 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Oncogene, 2016, 35(46):6026-6037

PubMed: 27157610 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Mol Oncol, 2016, 10(5):735-750

PubMed: 26775640 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2016, 3:16003

PubMed: 27626039 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2685-2692

PubMed: 27459069 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

J Cell Physiol, 2016, 231(3):650-8

PubMed: 26218437 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

Sci Rep, 2016, 6:30749

PubMed: 27480951 ( click the link to review the publication )

J Biol Chem, 2016, 291(16):8745-55

PubMed: 26912657 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:1393-1405

PubMed: 27802904 ( click the link to review the publication )

Retrovirology, 2016, 13(1):36

PubMed: 27206407 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Am J Transl Res, 2016, 8(9):3893-3902

PubMed: 27725868 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0148912

PubMed: 26859414 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

J Org Chem, 2016, 81(22):11324-11334

PubMed: 27768313 ( click the link to review the publication )
JCI Insight, 2016, 1(5):e85061

PubMed: 27699258 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27769045 ( click the link to review the publication )

Ann Rheum Dis, 2015, 10.1136/annrheumdis-2014-206258

PubMed: 25589513 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

Biomaterials, 2015, 73:110-9

PubMed: 26406451 ( click the link to review the publication )

Cancer Res, 2015,

PubMed: 26294211 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Arch Toxicol, 2015, 89(9):1599-618

PubMed: 26272509 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1447-1457

PubMed: 25957812 ( click the link to review the publication )

Mol Pharm, 2015, 12(7):2469-76

PubMed: 26030093 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29478-92

PubMed: 26491017 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074.jbc.M114.624361

PubMed: 25737447 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(12):1784-93

PubMed: 26529495 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2015, 5(3):117-26

PubMed: 26199860 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0126566

PubMed: 26176219 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134426

PubMed: 26247786 ( click the link to review the publication )

Pediatr Blood Cancer, 2015, 62(1):52-9

PubMed: 25308916 ( click the link to review the publication )
Exp Hematol, 2015, 43(6):448-61

PubMed: 25704054 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17698-712

PubMed: 25989842 ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(25):21507-21

PubMed: 26087189 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2088-100

PubMed: 25576920 ( click the link to review the publication )

Cancer Lett, 2014, 356(2 Pt B):656-68

PubMed: 25458954 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Anal Chem, 2014, 86(10):4642-7

PubMed: 24559101 ( click the link to review the publication )

Br J Cancer, 2014, 111(2):281-91

PubMed: 24946002 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Immunol, 2014, 193(3):1333-43

PubMed: 24973453 ( click the link to review the publication )

Mol Carcinog, 2014, 53(9):722-35

PubMed: 23475695 ( click the link to review the publication )

BMC Cancer, 2014, 14:17

PubMed: 24418474 ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):649-54

PubMed: 25193706 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Leukemia, 2013, 27(6):1291-300

PubMed: 23411464 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )
Cancer Lett, 2013, 329(1):17-26

PubMed: 22995071 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R58

PubMed: 23879992 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Stem Cells, 2013, 31(7):1434-45

PubMed: 23592435 ( click the link to review the publication )

Br J Haematol, 2013, 162(4):559-62

PubMed: 23692150 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):429-33

PubMed: 23932191 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1507-14

PubMed: 23824064 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1325-34

PubMed: 23515752 ( click the link to review the publication )

PLoS One, 2013, 8(8):e74253

PubMed: 23991216 ( click the link to review the publication )

PLoS One, 2013, 8(11):e79106

PubMed: 24244429 ( click the link to review the publication )

PLoS One, 2013, 8(9):e76662

PubMed: 24098799 ( click the link to review the publication )

PLoS One, 2013, 8(7):e69992

PubMed: 23922886 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Theriogenology, 2013, 80(6):630-5

PubMed: 23866857 ( click the link to review the publication )

Protein Expr Purif, 2013, 92(1):119-127

PubMed: 24056254 ( click the link to review the publication )

Genet Mol Res, 2013, 12(4):5405-13

PubMed: 24301913 ( click the link to review the publication )

The University of Western Ontario, 2013, CHAE YOUNG HAN

PubMed: ( click the link to review the publication )

Obstet Gynecol Int, 2013, 2013:828165

PubMed: 24381593 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Blood, 2012, 119(6):1450-8

PubMed: 22144178 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 131(3):777-89

PubMed: 21452019 ( click the link to review the publication )

J Neurooncol, 2012, 110(3):335-48

PubMed: 23054560 ( click the link to review the publication )
Acta Neuropathol, 2011, 122(5):637-50

PubMed: 21863243 ( click the link to review the publication )

PLoS One, 2011, 6(6):e20920

PubMed: 21687633 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Biochem Bioph Res Co, 2010, 391(4):1748-51

PubMed: 20043870 ( click the link to review the publication )

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述

靶点

HDAC (MOLT-4 cells) ^[1]	HDAC (Reh cells) ^[1]
5 nM	20 nM

体外研究

LBH589诱导MOLT-4和Reh细胞凋亡，这种作用具有时间和剂量依赖性。而且，LBH589作用于MOLT-4细胞比作用于Reh细胞更有效。LBH589明显阻止MOLT-4 和Reh细胞的生长，处理48小时，具有剂量依赖性。与对照组细胞相比，用LBH589处理的细胞，在细胞周期的G2/M期的细胞数量增多2到3倍。LBH589与组蛋白H3K9和H4K8的乙酰化作用相关，LBH589也降低c-Myc的表达水平，具有剂量依赖性。LBH589也增强p21的表达水平。最低剂量的LBH589（10 nM）处理Reh细胞，最初增强c-Myc的表达水平，之后一直降低c-Myc的表达水平。此外，LBH589促进mRNA水平的促凋亡和DNA修复基因的大量增多。在GADD45G启动子作用下，LBH589诱导乙酰化的组蛋白H3 和H4水平的增多。^[1]此外, LBH589抑制非小细胞肺癌细胞系生长，如人类H1299,L55和A549，IC50分别为5,11和30 nM；间皮瘤细胞生长，如人类OK-6和 Ok-5，IC50分别为5和7 nM；及小细胞肺癌细胞系生长，如人类RG-1和LD-T，IC50分别为4和5 nM。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT29	NGnTNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jSO\|AuOTBizszN	NXe4dZd4OC12IHS=		MXnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M1\aUVI3PzB{N{i0
HepG2	MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYriXmNEOC1zMDFOwG0>	NH\yPGQxNTRiZB?=		NHn0dJdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MWeyOlcxOjd6NB?=
HT29	M{PnNmZ2dmO2aX;uJGF{e2G7	NVTqZWFRPTEEoH7N	NHzoVJIzPC15MjDo		MonXbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UhOyCjZoTldkA1QMLiaNMg	MU[yOlcxOjd6NB?=
HepG2	NXrPZnJsTnWwY4Tpc44hSXO\|YYm=	MYK1NOKhdk1?	NUS5XJpROjRvN{KgbC=>		NFr3WFBqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB\|IHHmeIVzKDJ2wrDoxsA>	NXLSPXRVOjZ5MEK3PFQ>
HCC827	M2LXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXG1M\|cvPS9zMDDuUS=>	MV23NuKhcA>?	MmW3SG1UVw>?	M2G1foVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk	NHvHS2YzPjZ5NUS4OC=>
A549	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfQXooyOTBxMUWvNlAhdk1?	M4LMSlczyqCq	NIKy[HJFVVOR	NVjDbXR2\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK=	MnqxNlY3PzV2OES=
NCI-H460	M{i0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M372e\|ExNzJyL{OwJI5O	M2XrflczyqCq	Mm\jSG1UVw>?	NX3UZ2tQ\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK=	NFvCb5UzPjZ5NUS4OC=>
J89GFP	M{jWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVnEUXNQyqB?	MnHFSWM2OD12OT64OUDDuSBzMj62OUBvVQ>?	NHLXe2UzPjV4M{W2PC=>
THP89GFP	NInN[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MY\EUXNQyqB?	NXW4UXBLTUN3ME2xPU4{PCEEsTC2MlQ{KG6P	MkLxNlY2PjN3Nki=
SK-NEP-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;rWWp{OC5yMfMAl\|ExNjBizszN	NHXYZZkzPCCq	M1LI[2ROW00EoB?=	NFT5dWhKSzVyPUe2MlM1KG6P	NYTYOXZXOjZzN{[yNVk>
G401	MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfv[HFlOC5yMfMAl\|ExNjBizszN	NYW4dnZIOjRiaB?=	MXTEUXNQyqB?	MUfJR\|UxRTF2Mz6wNkBvVQ>?	MXyyOlE4PjJzOR?=
SK-NEP-1	MWLD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NWrBV3FJPTBibl2=	NEm5OnYy6oDVNDDk	M3PrVmROW00EoB?=	MYTy[YR2[2W\|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	Mnz4NlYyPzZ{MUm=
G401	MWDD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mm\lOVAhdk1?	M1zLblHjiJN2IHS=	Mm\nSG1UV8Li	NEHrb5lz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ?	Ml;sNlYyPzZ{MUm=
SK-NEP-1	NWfBPJJESXCxcITvd4l{KEG\|c3H5	Mn\ZOVAwOTByIH7N	NXT4e2hXOjRiaB?=	M3vwe2ROW00EoB?=	NETNcVdqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NITHO3kzPjF5NkKxPS=>
G401	NHiyV\|NCeG:ydH;zbZMhSXO\|YYm=	MYC1NE8yODBibl2=	M4nqNlI1KGh?	M3OzWmROW00EoB?=	MlrBbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M1XiZVI3OTd4MkG5
SK-NEP-1	MXTGeY5kfGmxbjDBd5NigQ>?	M{DHRVUxNzFyMDDuUS=>	M{XMWlI1KGh?	MUfEUXNQyqB?	MmDMd4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>?	M3\TXFI3OTd4MkG5
G401	Mk\MSpVv[3Srb36gRZN{[Xl?	MYq1NE8yODBibl2=	MUmyOEBp	NVLvW3JUTE2VT9Mg	M2\M[pNpd3e\|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25?	MnvONlYyPzZ{MUm=
SK-NEP-1	M1TIU2Z2dmO2aX;uJGF{e2G7	MnS3OVAwOTByIH7N	NXvIPIJ3OjRiaB?=	MnXUSG1UV8Li	NXvtTXJkcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB?	M1;pZ\|I3OTd4MkG5
G401	Mn;jSpVv[3Srb36gRZN{[Xl?	NGrtXFI2OC9zMECgcm0>	Mnu0NlQhcA>?	MlrHSG1UV8Li	NY\5PFZ6cW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB?	M2XTdFI3OTd4MkG5
RPMI 8226	MlX0R4VtdCCVdYL2bZZidCCDc4PhfS=>	MoHGNk81NzZibl2=	NX2xdGJPPDkkgJno		NXWyXFBpcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?=	NYPrZoE6OjZyMECyPVI>
OPM2	M3fkXGNmdGxiU4Xyeol3[WxiQYPzZZk>	NHjxRpMzNzRxNjDuUS=>	MWe0PQKBkWh?		M3npc4lv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh?	NWm5VlNuOjZyMECyPVI>
U266	NW\QPIdsS2WubDDTeZJ3cX[jbDDBd5NigQ>?	MYCyM\|QwPiCwTR?=	NV;3UlZtPDkkgJno		M2XGSIlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh?	M1Xwb\|I3ODByMkmy
H929	M4\wN2NmdGxiU4Xyeol3[WxiQYPzZZk>	NVjHSHBNOi92L{[gcm0>	NEfF[Fk1QOLCiXi=		NVrJOnJWcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?=	NUnhfWlMOjZyMECyPVI>
RPMI 8226	NYT6VlRVSXCxcITvd4l{KEG\|c3H5	MYW05qCKdk1?	MUSyOE81QCCq		M2r5dolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	Mn\aNlYxODB{OUK=
HCC827	M3LkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\lc\|lqOTBibl2=	M4LkOlQ5KGh?	MonESG1UVw>?	NUjmfYN{\W6qYX7j[ZMh[2m\|cHzheIlvKHOnboPpeIl3cXS7wrC=	MUGyOVk1PDZzNx?=
NCI-H23	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoThNVAhdk1?	MkjaOFghcA>?	MnLoSG1UVw>?	NHzmbWpmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?=	M{LnR\|I2QTR2NkG3
AML3	MomySpVv[3Srb36gRZN{[Xl?	NUHOc3k6OC1zIN88US=>	Mln5NlTDqGh?		MkTObY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NGXzO20zPTZzMkm0NS=>
ML-1	MWPGeY5kfGmxbjDBd5NigQ>?	MkLHNE0yKM7:TR?=	NUnhVJQ6OjUEoHi=		Mn3LbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NUDnd4diOjV4MUK5OFE>
RPMI-8226vr10	MVnGeY5kfGmxbjDBd5NigQ>?	MWiwMVEh\|ryP	MmLXNlTDqGh?		MoHXbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NXLsZoh4OjV4MUK5OFE>
ML-1	NEPyUo5HfW6ldHnvckBCe3OjeR?=	M2rwWlEh\|ryP	MXeyOOKhcA>?		NHvETHJqdmO{ZXHz[ZMh[2G\|cHHz[U0{KGGldHn2bZR6KDRvZn;s[C=>	M{Hj[VI2PjF{OUSx
RPMI-8226vr10	MmDTSpVv[3Srb36gRZN{[Xl?	M{TFS\|Eh\|ryP	MlvFNlTDqGh?		Ml;KbY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUAzNjVvZn;s[C=>	NETuN3kzPTZzMkm0NS=>
SK-N-BE (2)	NVziW2c{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{K1blI16oDLaB?=		NGrJ[GtKSzVyPUGwOE4x6oDLwsJihKk4Njhibl2=	NIHUR5YzPTNyOEmxOi=>
SK-N-BE (2), PAN MK	MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGHIU3AzPOLCiXi=		NYXVS29lUUN3ME2xNFQvOOLCidMx5qCKPy56IH7N	MmH2NlU{ODh7MU[=
SK-N-BE (2), MK PAN	M3HGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUj4NIpMOjUkgJno		M2C0WGlEPTB;M{iyMlDjiIoEsfMAjVQ{NjJibl2=	NEDSeG8zPTNyOEmxOi=>
SK-N-AS	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NETRPFUzPOLCiXi=		M{DNemlEPTB;M{euNgKBkcLz4pEJNk41KG6P	M33GUVI2OzB6OUG2
SK-N-DZ	MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml\iNlTjiImq		NUnKPWlLUUN3ME2xO{4y6oDLwsJihKkxNjRibl2=	M2fsV\|I2OzB6OUG2
Caki-1	M{TjVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;ZXlExNzJ3L{WwJI5O	NUHHeGhoPDhiaB?=		NVjrdmdEcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny	M1\SblI2Ojd7MUmx
ACHN	NHm5b3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXENVAwOjVxNUCgcm0>	M3zKOFQ5KGh?		NHfBOJRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK=	NFjIRYgzPTJ5OUG5NS=>
769-P	MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17qNlExNzJ3L{WwJI5O	NEnkOVA1QCCq		M2HHdIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?=	MmHPNlUzPzlzOUG=
786-O	M4C4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfoSFhmOTBxMkWvOVAhdk1?	MXm0PEBp		MWnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ?	NYPZcXBOOjV{N{mxPVE>
Caki-1	M33JcmFxd3C2b4Ppd{BCe3OjeR?=	NF[2S\|A2OCCwTR?=	MUK0PEBp		MlmybY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ?	MX:yOVI4QTF7MR?=
ACHN	MXTBdI9xfG:\|aYOgRZN{[Xl?	NXm2blJ[PTBibl2=	M2C1cVQ5KGh?		NHLlW4JqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	NYXpUolJOjV{N{mxPVE>
769-P	NGTxNXVCeG:ydH;zbZMhSXO\|YYm=	MWS1NEBvVQ>?	NHP1NpU1QCCq		NFjNT3lqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	MYGyOVI4QTF7MR?=
786-O	M2\BUGFxd3C2b4Ppd{BCe3OjeR?=	MnfCOVAhdk1?	M2rSdlQ5KGh?		MVfpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>?	MWWyOVI4QTF7MR?=
Caki-1	MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW[yOU82OCCwTR?=	MVm0PEBp	M2DOZ2ROW09?	Mo\QbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?=	M2XUd\|I2OTd4M{W0
ACHN	NGXiUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\tUnEzPS93MDDuUS=>	Mn3qOFghcA>?	NYLHOlNVTE2VTx?=	M3zQcYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK=	NX;JO\|FxOjVzN{[zOVQ>
769-P	NWHOV3ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvCWpgzPS93MDDuUS=>	NEXnZYg1QCCq	MULEUXNQ	M4DuXYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK=	MUSyOVE4PjN3NB?=
Caki-1	NWm3U2p1S2:ub375JGZwem2jdHnvckBCe3OjeR?=	MV[1NEBvVQ>?	Mn\GO{0yPCCm	MnLrSG1UVw>?	MnX5d5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA>	M3LOfFI2OTd4M{W0
ACHN	Ml;hR49td267IF\vdo1ifGmxbjDBd5NigQ>?	MXW1NEBvVQ>?	MXi3MVE1KGR?	NYqwNZZZTE2VTx?=	MoLTd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA>	Mm\0NlUyPzZ\|NUS=
769-P	MmjNR49td267IF\vdo1ifGmxbjDBd5NigQ>?	NH7od4U2OCCwTR?=	MnnWO{0yPCCm	MkDsSG1UVw>?	NULV[YRye3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB?	MnrsNlUyPzZ\|NUS=
Caki-1	MYXBdI9xfG:\|aYOgRZN{[Xl?	NYThUohTPTBibl2=	M4rt[\|Q5KGh?	NUH0N5dbTE2VTx?=	MorMbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MXqyOVE4PjN3NB?=
ACHN	MkLaRZBweHSxc3nzJGF{e2G7	M4[1dlUxKG6P	M2iyNFQ5KGh?	MX;EUXNQ	NYHwcYhJcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MYeyOVE4PjN3NB?=
769-P	NYLzZoF6SXCxcITvd4l{KEG\|c3H5	NFW5WXM2OCCwTR?=	M1v3dFQ5KGh?	M3rmdWROW09?	M1vjR4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MWKyOVE4PjN3NB?=
MDA-MB-231	MWTNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk>	M2nRWFExyqCwTR?=	MUGzxsBl	NYHHXnhHTE2VTx?=	MmThZYx1\XK\|IHPlcIwhdW:{cHjvcI9ogcLi	MXiyOFgyODR7Nx?=
BT-549	MXnNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk>	MYmxNOKhdk1?	MV2zxsBl	NYLCeXNCTE2VTx?=	MmraZYx1\XK\|IHPlcIwhdW:{cHjvcI9ogcLi	NYHIeVdFOjR6MUC0PVc>
MCF-7	NGPWWG9Od3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl?	MX6xNOKhdk1?	NXTpdnc5O8LiZB?=	MVjEUXNQ	Mmj5ZYx1\XK\|IHPlcIwhdW:{cHjvcI9ogcLi	MWqyOFgyODR7Nx?=
MCF-7	NUW1eI1lTnWwY4Tpc44hSXO\|YYm=	MY[1MVUxKG6P	MomyNlQhcA>?	NG\SZYJFVVOR	NEPN[nNz\WS3Y3XkJJRp\SCuZY\lcEBw\iCneIDy[ZN{cW:wIH;mJGVT\|rFuIGDSJIFv\CCIb4jBNeKh	NXXtXpVQOjR\|Nk[0NFc>
CTS	Ml\MRZBweHSxc3nzJGF{e2G7	NUfUR3IxOOLCk{SwJI5OyqB?	NHLFNYg1QCCq		NI[2VGxqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	Ml\1NlQzPDR2Mkm=
OCI-AML3	MkS3RZBweHSxc3nzJGF{e2G7	NY\yeXNzOOLCk{SwJI5OyqB?	MVW0PEBp		MoT1bY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NY\ye4l5OjR{NES0Nlk>
U937	NVTUSm03SXCxcITvd4l{KEG\|c3H5	MluyNQKBmzRyIH7NxsA>	NWXYU5hyPDhiaB?=		Mm\abY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MWSyOFI1PDR{OR?=
PC3	NIDRRm9CeG:ydH;zbZMhSXO\|YYm=	M{fIOVAuOTByIH7N	MmnqNlQwPDhiaB?=		MXHpcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MYmyOFE3OzJ\|MB?=
PC3-AR	M{fKfGFxd3C2b4Ppd{BCe3OjeR?=	MVSwMVExOCCwTR?=	M3LIS\|I1NzR6IHi=		NX;QRmpscW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M1:2clI1OTZ\|MkOw
PC3	NUXWNGI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fxO\|AuOTByIH7N	NX3sVnRTOjRxNEigbC=>		M4XEOYlv\HWlZYOgZYNkfW23bHH0bY9vKG:oIIP1ZmcyKHCxcIXsZZRqd25?	M3zVcVI1OTZ\|MkOw
PC3-AR	NGfj[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPFNE0yODBibl2=	NIDDPIIzPC92ODDo		MoezbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dDDpckB1cGViR{LNJJBp[XOn	MUSyOFE3OzJ\|MB?=
PC3	NGjQdFdHfW6ldHnvckBCe3OjeR?=	MkTINE0yODBibl2=	MVuyOEBp		NX;EbXNje3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4>	MV2yOFE3OzJ\|MB?=
PC3-AR	NWj2O4ZtTnWwY4Tpc44hSXO\|YYm=	MmPCNE0yODBibl2=	NUK4fYV7OjRiaB?=		MnjLd5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6=	MViyOFE3OzJ\|MB?=
OS-RC-2	MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NUn1[mVEOC1zMECwJI5O	MYWyOE81QC95MjDo	MmjUSG1UVw>?	M3\wWoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MVKyOFE1PDd\|Nx?=
OS-RC-2	MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVeyd\|lUPTBibl2=	M4q5[lQ5KGh?	M4DLeGROW09?	Mn\DbY5lfWOnczDHNk9OKGG{cnXzeC=>	NH7TSIkzPDF2NEezOy=>
OS-RC-2	NV3jS49OSXCxcITvd4l{KEG\|c3H5	NHHDS\|U2OCCwTR?=	NInt[Gg1QCCq	M{XmNGROW09?	MULpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NYDUcmJHOjRzNES3N\|c>
SK-N-AS	M{\qU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvkXlUx6oDVOECgcm0>	M{XLeFQ5KGh?		NYr6R3JbUUN3ME2yO{41KG6P	NVniPFZyOjRyOUi3PVk>
SK-N-DZ	NVnVZ3VpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1K4bVDjiJN6MDDuUS=>	NH7ZfY81QCCq		NVrxW3g3UUN3ME2yNU46KG6P	NEj4WYczPDB7OEe5PS=>
SK-N-SH	NV\Id2lMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DTcFDjiJN6MDDuUS=>	MlXROFghcA>?		NHrw[nhKSzVyPUeyMlMhdk1?	NHP2W5czPDB7OEe5PS=>
SK-N-BE	MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7pcWV5OOLCk{iwJI5O	M3TZN\|Q5KGh?		NXvvblRoUUN3ME23OU41KG6P	NF;nOIwzPDB7OEe5PS=>
SK-N-AS	M4W4PWFxd3C2b4Ppd{BCe3OjeR?=	NFHIPGsx6oDVOECgcm0>	NHvkcnc1QCCq		NYXUbnF3eG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v	MmXlNlQxQTh5OUm=
SK-N-DZ	MknCRZBweHSxc3nzJGF{e2G7	MXyw5qCUQDBibl2=	NGDxfXY1QCCq		MojpdI91\W62bImgbY5lfWOnZDDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	MXSyOFA6QDd7OR?=
SK-N-SH	NXPBUmlCSXCxcITvd4l{KEG\|c3H5	NHvGV2Ex6oDVNECgcm0>	NIDlW201QCCq		M33xdpBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG\|aHnvci=>	MVOyOFA6QDd7OR?=
SK-N-BE	M4j6UGFxd3C2b4Ppd{BCe3OjeR?=	MlLvNQKBmzRyIH7N	NHvDPWw1QCCq		Mn7tdI91\W62bImgbY5lfWOnZDDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	M1\zUlI1ODl6N{m5
SK-N-AS	NFflSnhHfW6ldHnvckBCe3OjeR?=	NGXjPIkx6oDVOECgcm0>	MUG0PEBp		MYXpcoR2[2W\|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG\|ZTCzJIFv\CCSQWLQ	M{K3eVI1ODl6N{m5
SK-N-DZ	M3HOUGZ2dmO2aX;uJGF{e2G7	M4j6XVDjiJN6MDDuUS=>	MWS0PEBp		NHHueIRqdmS3Y3XzJIEh\G:\|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[UA{KGGwZDDQRXJR	MlPTNlQxQTh5OUm=
SK-N-SH	MYfGeY5kfGmxbjDBd5NigQ>?	M{HQWFDjiJN2MDDuUS=>	M1f2fFQ5KGh?		NXLlOph2cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>?	NEjZVIszPDB7OEe5PS=>
SK-N-BE	NGXI[3VHfW6ldHnvckBCe3OjeR?=	MmjmNQKBmzRyIH7N	NGDBW\|M1QCCq		NEnhPVhqdmS3Y3XzJIEh\G:\|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[UA{KGGwZDDQRXJR	MlnwNlQxQTh5OUm=
HCC-LM3	NIf4O3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFz0cFIyNTFyMECgcm0>	M4H3fVI1NzR6L{eyJIg>	M{T4OWROW09?	NU\QdWZxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NXm0Sm06OjRyOUO5OVY>
HepG2	Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnPXm0yNTFyMECgcm0>	NX35cG06OjRxNEivO\|IhcA>?	NV\XVmJjTE2VTx?=	MWfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NYO5bGRKOjRyOUO5OVY>
SMMC-7721	NIj0OY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7XNU0yODByIH7N	NVn6VplROjRxNEivO\|IhcA>?	NFTyenZFVVOR	Mn:0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NWnvTXRpOjRyOUO5OVY>
HCC-LM3	NUjJOFNYSXCxcITvd4l{KEG\|c3H5	MWe1NEBvVQ>?	NGqzNXo1QCCq	MlzTSG1UVw>?	MnLibY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk>	NUT0cYY2OjRyOUO5OVY>
HepG2	MV\BdI9xfG:\|aYOgRZN{[Xl?	NFzFVnE2OCCwTR?=	NUjqRlBHPDhiaB?=	NVvhWGRmTE2VTx?=	NF3NOXRqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMhOyxiODDhcoQhQQ>?	M{L1XVI1ODl\|OUW2
SMMC-7721	NIf0NmVCeG:ydH;zbZMhSXO\|YYm=	M2j3fFUxKG6P	NWTo[HhFPDhiaB?=	MWfEUXNQ	NYDXfZBRcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG\|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl?	NVvEOY54OjRyOUO5OVY>
HCC-LM3	Mm\NSpVv[3Srb36gRZN{[Xl?	MkfSOVAwOTByIH7N	Mm\yNlQhcA>?	NF3rW5BFVVOR	M4n3doRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC=	MlTsNlQxQTN7NU[=
HepG2	NV[3Zot{TnWwY4Tpc44hSXO\|YYm=	NXfQ[5ZIPTBxMUCwJI5O	NEnNO4IzPCCq	NIX2ZZpFVVOR	M2nVdoRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC=	MXyyOFA6Ozl3Nh?=
SMMC-7721	MYTGeY5kfGmxbjDBd5NigQ>?	MnHIOVAwOTByIH7N	MXqyOEBp	MYHEUXNQ	NUfCOXZx\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=>	MXOyOFA6Ozl3Nh?=
HCC-LM3	MlfqSpVv[3Srb36gRZN{[Xl?	MXe1NE8yODBibl2=	MkLqNlQhcA>?	NYDP[IZRTE2VTx?=	Mn3K[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>?	NWO4dndvOjRyOUO5OVY>
HepG2	M2rteGZ2dmO2aX;uJGF{e2G7	Mn3TOVAwOTByIH7N	M3mxeVI1KGh?	NF\MeFBFVVOR	NHW5TYZld3ewcnXneYxifGW\|IFLjcE15VCCneIDy[ZN{cW:w	NY\C[GE{OjRyOUO5OVY>
SMMC-7721	MV7GeY5kfGmxbjDBd5NigQ>?	NX3t[YZqPTBxMUCwJI5O	NUHM[GY{OjRiaB?=	M13GVGROW09?	MVPkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v	MlHINlQxQTN7NU[=
FaDu	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTjNVAx6oDHbl2=	NITyPWE5NzFyL{GyJIg>		MlPF[Il{eGyjeXXkJIEhe2mpbnnmbYNidnRiYX7kJJBzd2yxbnfl[EBIOi:PIHHydoV{fCCjdDC4JIFv\CBzMvMAiYgheG:\|dDDy[Yxm[XOn	MY[yOFAzPjR6Mh?=
FaDu	NWjRWZdWTnWwY4Tpc44hSXO\|YYm=	Mnm4NVAx6oDHbl2=	MlHSNk81NzhxMUKgbC=>		NGDOeHBqdmS3Y3XkJJAzOVejZkGvR4lxOcLiZYjwdoV{e2mxbh?=	MWSyOFAzPjR6Mh?=
PC-3	NWTtdXM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1f2bFAuOTBizszN	Ml36NlQwPDhxN{KgbC=>		MkW2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NETCZpEzOzl7MUKxOi=>
LNCaP	M1\tdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGm4SIIxNTVizszN	NVLWUXZVOjRxNEivO\|IhcA>?		MoHhbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NGfYfm0zOzl7MUKxOi=>
RWPE-1	MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVGwMVIxKM7:TR?=	NWLsfVVFOjRxNEivO\|IhcA>?		MlGybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	Ml7HNlM6QTF{MU[=
Capan-1	MmO5SpVv[3Srb36gRZN{[Xl?	NYLGT497OjVxNUCvNVAxKG6P	MlLUPE8zPC92ODDo	M13FeGROW09?	NEL1ZYpld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n	NIWwXZUzOzl{Mki4Oi=>
L3.6pl	NVzU[ldjTnWwY4Tpc44hSXO\|YYm=	MYOyOU82OC9zMECgcm0>	NVHi[nBVQC9{ND:0PEBp	M2LLc2ROW09?	MWfkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p	MY[yN\|kzOjh6Nh?=
CFPAC-1	M{W1fWZ2dmO2aX;uJGF{e2G7	MUOyOU82OC9zMECgcm0>	NEPmVZk5NzJ2L{S4JIg>	MUXEUXNQ	NF7VZ2pld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n	NGfne5EzOzl{Mki4Oi=>
Capan-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWSyb5BuOjVxNUCvNVAxKG6P	NVn0N2xSPDhiaB?=	M3zjOWROW09?	MWXy[YR2[2W\|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NIDKbXAzOzl{Mki4Oi=>
L3.6pl	MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVKyOU82OC9zMECgcm0>	MnLmOFghcA>?	MoPESG1UVw>?	M{L6cJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NF;WUlUzOzl{Mki4Oi=>
CFPAC-1	NVXaTmJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPMPHQzPS93MD:xNFAhdk1?	MUe0PEBp	NFfOfmFFVVOR	M4HUcJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NGPKSXUzOzl{Mki4Oi=>
Capan-1	NYHkUGlpSXCxcITvd4l{KEG\|c3H5	NIPXeIwzPS93MD:xNFAhdk1?	NWXNTJVKPDhiaB?=	MVnEUXNQ	NHTnbJRqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NETsXYszOzl{Mki4Oi=>
L3.6pl	MlvmRZBweHSxc3nzJGF{e2G7	MorZNlUwPTBxMUCwJI5O	NXTafYIxPDhiaB?=	MXzEUXNQ	M3XMWYlv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MnHzNlM6OjJ6OE[=
CFPAC-1	NXHYOYF7SXCxcITvd4l{KEG\|c3H5	NF61RXUzPS93MD:xNFAhdk1?	M3\IUlQ5KGh?	MkTqSG1UVw>?	MXPpcoR2[2W\|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MknnNlM6OjJ6OE[=
HN22	NWT0ZnRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYCwMVIxKG6P	MlO1NlQwPDhiaB?=	MoPWSG1UVw>?	Mki3bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=>	NEHRSHUzOzh5N{KzOS=>
HSC4	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrRd5JiOC1{MDDuUS=>	NXznXIVQOjRxNEigbC=>	MlrYSG1UVw>?	NFnjZ2lqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz	NUfyeZFWOjN6N{eyN\|U>
HN22	MnPERZBweHSxc3nzJGF{e2G7	M{TuSlAuOjBibl2=	NGrlcXM1QCCq	M{S0UmROW09?	MXXpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NXfRWGo4OjN6N{eyN\|U>
HSC4	MVzBdI9xfG:\|aYOgRZN{[Xl?	NFK3bXExNTJyIH7N	MX[0PEBp	NVzydIc6TE2VTx?=	MYPpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MVyyN\|g4PzJ\|NR?=
HN22	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkGzNE0zOCCwTR?=	M33WdVQ5KGh?	NIGxTVBFVVOR	MnzKbY5lfWOnczDHNUBxcGG\|ZTDj[YxtKGO7Y3zlJIFzemW\|dNMg	Ml2wNlM5Pzd{M{W=
HSC4	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoCwNE0zOCCwTR?=	MkTNOFghcA>?	MWPEUXNQ	M3G4OIlv\HWlZYOgS\|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=>	NWnPcYtYOjN6N{eyN\|U>
HN22	NWH5V4xGTnWwY4Tpc44hSXO\|YYm=	NGjYSVExNTJyIH7N	M1TpZlQ5KGh?	NXyyV3dMTE2VTx?=	M4H4N5N2eHC{ZYPz[ZMhW3BzIHX4dJJme3Orb39CpC=>	NG\NTGozOzh5N{KzOS=>
HSC4	MXTGeY5kfGmxbjDBd5NigQ>?	MV[wMVIxKG6P	MmSzOFghcA>?	M{fvbWROW09?	MoK0d5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg	MWmyN\|g4PzJ\|NR?=
Cal62	NUXrOpVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTN\|INMxJFQhdk1?	MXWyN\|gzPDB4NB?=
Hth7	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVz5PXlDUUN3ME2xOUDDuSB{IH7N	NVHlU2xtOjN6MkSwOlQ>
Hth83	NHXoOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoryTWM2OD1\|NDFCtUA2KG6P	M2fTelI{QDJ2ME[0
C643	M3e2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTdzINMxJFExKG6P	MkDSNlM5OjRyNkS=
SW1736	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjyTWM2OD1\|NTFCtUA5KG6P	M4fkXFI{QDJ2ME[0
T241	NXi2T5U6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPtSFlyUUN3ME22OUDDuSB5IH7N	MkPqNlM5OjRyNkS=
T351	NFS1OYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\RU2lEPTB;NUCgxtEhOTBibl2=	MXGyN\|gzPDB4NB?=
BHP2-7	Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVH3ZZl{UUN3ME2zO{DDuSB4IH7N	NUPFZlczOjN6MkSwOlQ>
T238	NHfMS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DJS2lEPTB;MTy1NFAhyrFiMkCwJI5O	Moi1NlM5OjRyNkS=
HCT8	M3TQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4e1bFczKGh?	NGLOVG5FVVOR	NVzlNXJOUUN3ME2xNk466oDLwsJihKkyNjlibl2=	NYLRdYVnOjN{OUmzPFg>
H630	NE\BN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIH4N3U4OiCq	MoTXSG1UVw>?	MlvuTWM2OD1zMj605qCKyrIkgJmzMlEhdk1?	NW[4VG1[OjN{OUmzPFg>
cH630 5-FU-res	NHThd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVq3NkBp	NFzMN3dFVVOR	MnLoTWM2OD1zNT615qCKyrIkgJmxMlIhdk1?	NGPwNVUzOzJ7OUO4PC=>
HCT116	NXjXc4pjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWLxfI93PzJiaB?=	M{Kwb2ROW09?	M1nWNGlEPTB;MUCuO-KBkcLz4pEJNk4zKG6P	MYeyN\|I6QTN6OB?=
HCT116 p53−/−	MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX;OXpJrPzJiaB?=	NHLzXIZFVVOR	MX;JR\|UxRThwNvMAjeKy6oDLMT63JI5O	NYLzT2lnOjN{OUmzPFg>
dHCT116 p21−/−	NV;lNnltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MU[3NkBp	NX;N[XBITE2VTx?=	MnfaTWM2OD13LkpihKnDueLCiUGuN{BvVQ>?	MWSyN\|I6QTN6OB?=
HT29	NH3sN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHLsNWM4OiCq	MUDEUXNQ	MnnwTWM2OD1zNj6z5qCKyrIkgJmyMlMhdk1?	M3zwS\|I{Ojl7M{i4
LoVo	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4rmOFczKGh?	NFu4dZhFVVOR	M3nBeGlEPTB;NT6x5qCKyrIkgJmwMlYhdk1?	NIjpd4czOzJ7OUO4PC=>
RKO	MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MW[3NkBp	NUHmUHBnTE2VTx?=	MYrJR\|UxRTdwOfMAjeKy6oDLMj6yJI5O	NY\yO2RPOjN{OUmzPFg>
SW480	NYPpbZRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWjqS5VMPzJiaB?=	NYPu[2VJTE2VTx?=	M33tbWlEPTB;MUeuOgKBkcLz4pEJNE45KG6P	NFfufnIzOzJ7OUO4PC=>
eSW620	NHG4[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml3lO\|IhcA>?	MUDEUXNQ	MXrJR\|UxRTlwMfMAjeKy6oDLMj6xJI5O	NYDCR3NjOjN{OUmzPFg>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 / EZH2; PubMed: 19279403 Cancer Biol Ther Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control. caspase-8 / cleaved caspase-8 / Sp1; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. c-Myc / IRF4; PubMed: 27738323 Oncotarget RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting. Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; PubMed: 28915627 Oncotarget Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1. RAD51 / BRCA1 / CHK1 / RPL13a; PubMed: 24244429 PLoS One CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells. H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; PubMed: 31071955 Int J Mol Sci Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.	19279403 27738323 28915627 24244429 31071955
Immunofluorescence	Synaptophysin / NACM; PubMed: 28915627 Oncotarget Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm. α-tubulin / Acetyl-α-tubulin; PubMed: 29983882 Oncotarget CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm. BiP; PubMed: 23544167 Transl Oncol Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. ATF4; PubMed: 23544167 Transl Oncol HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. IRE1α / S724-IRE1α; PubMed: 23544167 Transl Oncol Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.	28915627 29983882 23544167
Growth inhibition assay	Cell viability; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.	27738323

体内研究

LBH589作用于患肺癌和间皮瘤动物模型,明显降低肿瘤生长，与对照组相比平均降低62%。LBH589作用于免疫活性鼠和严重联合免疫缺陷鼠效果差不多，说明LBH589抑制肿瘤生长与免疫学无关。LBH589按20 mg/kg剂量腹腔注射，每周持续5天，导致在实验最后肿瘤生长平均下降70%。与相应的对照组肿瘤相比，LBH589作用于H526衍生的肿瘤下降53%，作用于BK-T衍生的肿瘤下降81%, 作用于RG-1衍生的肿瘤下降76%，作用于H69衍生的肿瘤下降 70%。在相同条件和剂量的情况下，LBH589 作用于NSCLC和Meso衍生的移植瘤，导致SCLC衍生的肿瘤中有两种衰退，伴随着BK-T衍生的平均肿瘤尺寸从实验开始时的296 mm³降低到实验结束时的116 mm³，RG-1衍生的平均肿瘤尺寸从实验开始时的185mm³降低到实验结束时的86 mm³。^[2]

细胞实验：^[1]	- 合并 Cell lines: MOLT-4细胞和Reh(前体B细胞) Concentrations: 50 nM Incubation Time: 48小时 Method: 没有处理的细胞和LBH589处理的细胞[人类急性成淋巴细胞性白血病MOLT-4(T 细胞)和Reh(前体-B细胞)]用膜联蛋白V和碘化丙啶染色，然后加入膜联蛋白V-FITC细胞凋亡检测试剂盒I。通过流式细胞仪测定细胞凋亡和不能存活细胞的百分比。用CyAn ADP Violet细胞计数器收集至少5×10⁴个细胞。根据所有的膜联蛋白V-阳性和膜联蛋白V/PI-阳性细胞细胞计算凋亡百分比，根据所有的膜联蛋白V-阳性和PI-阳性及膜联蛋白V/PI-阳性细胞计算细胞活力丢失百分比。 (Only for Reference)
动物实验：^[2]	- 合并 Animal Models: 携带10×10⁶个M30细胞或5×10⁶个A549细胞的SCID鼠 Dosages: 10 mg/kg, 20 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	69 mg/mL (197.46 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+48% PEG 300+2% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Panobinostat (LBH589) SDF

分子量	349.43
化学式	C₂₁H₂₃N₃O₂
CAS号	404950-80-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	NVP-LBH589

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04341311	Recruiting	Drug: Marizomib\|Drug: Panobinostat	Diffuse Intrinsic Pontine Glioma\|Pediatric Brainstem Glioma\|Pediatric Brainstem Gliosarcoma Recurrent\|Pediatric Cancer\|Pediatric Brain Tumor\|Diffuse Glioma	Dana-Farber Cancer Institute\|Celgene\|Secura Bio	August 2020	Phase 1
NCT03632317	Withdrawn	Drug: Panobinostat\|Drug: Everolimus	Glioma\|Diffuse Intrinsic Pontine Glioma	University of Michigan Rogel Cancer Center	October 2019	Phase 2
NCT03982134	Withdrawn	Drug: PDR001\|Drug: Panobinostat	Melanoma\|Non Small Cell Lung Cancer	Muhammad Furqan\|Novartis Pharmaceuticals\|University of Iowa	September 2019	Phase 1
NCT04326764	Recruiting	Drug: Panobinostat	Acute Myeloid Leukaemia (AML)\|Myelodysplastic Syndromes (MDS)	Goethe University\|Jan J. Cornelissen (HOVON-SAKK)\|Sebastian Giebel (PALG)	July 24 2018	Phase 3
NCT03515915	Unknown status	--	Patients With Recurrent or Refractory Multiple Myeloma	University Hospital Montpellier\|Poitiers University Hospital	April 23 2018	--

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How to reconstitute the compound for in vivo mice study?
回答：
We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

选择性强的HDAC抑制剂

RGFP966 : HDAC3-selective, IC50=80 nM.
选择性强的HDAC抑制剂

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
活性最高的HDAC抑制剂

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA批准的HDAC抑制剂

Vorinostat (SAHA, MK0683) : Approved by FDA for cutaneous T cell lymphoma.
最新的HDAC抑制剂

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

研究领域

产品类型

定制您的化合物库

Panobinostat (LBH589)

客户使用Selleck生产的Panobinostat (LBH589)发表文献269篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Panobinostat (LBH589) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-09-01)

技术支持

常见问题及建议解决方法

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品